Maximus Earnings Call Transcripts
Fiscal Year 2026
-
Q2 delivered strong profitability and margin gains from technology investments, with revenue and cash flow in line with guidance. Raised full-year earnings outlook, expanded share repurchase program, and expect improved cash flow as DSO normalizes.
-
The meeting covered director elections, auditor ratification, and executive compensation, with all proposals passing. Shareholders could submit questions, and final voting results will be filed with the SEC.
-
Q1 results met expectations, with revenue of $1.35B and improved margins. FY26 guidance was raised for earnings and narrowed for revenue, reflecting divestitures and delayed new work. Technology-driven solutions and legislative changes in Medicaid and SNAP are expected to drive future growth.
Fiscal Year 2025
-
Fiscal 2025 saw higher-than-expected revenue and profitability, with strong growth in U.S. federal services and significant investments in AI and technology. Fiscal 2026 guidance anticipates margin expansion and robust cash flow, despite a slight revenue dip, as the company positions for major growth opportunities in 2027 and beyond.
-
Record Q3 results with 24% EPS growth and 15% adjusted EBITDA increase, leading to raised full-year guidance. Strong federal segment performance, new legislative opportunities, and a major DoD contract support a positive outlook, with cash flow and leverage expected to normalize.
-
Q2 revenue grew 1% (3% organic) to $1.36B, with adjusted EBITDA margin at 13.7% and EPS at $2.01. Guidance for FY25 was raised, reflecting strong federal segment growth and operational efficiencies, while the pipeline remains robust despite procurement delays and macro uncertainty.
-
Strong Q1 results with 5.7% revenue growth and raised full-year guidance, driven by robust U.S. Federal Services performance, successful contract wins, and strategic divestitures. Accelerated share repurchases and a healthy pipeline support continued optimism.
Fiscal Year 2024
-
Organic revenue grew 8.8% and adjusted EPS reached a record $6.11 in FY 2024, with strong cash flow and margin expansion. FY 2025 guidance projects stable revenue and margins, with a robust pipeline and prudent risk management amid administrative transition.
-
Q3 saw 10.6% revenue growth and margin expansion, prompting a third consecutive guidance raise. Non-recurring Medicaid and federal program volumes drove overperformance, with FY25 expected to normalize but maintain strong margins and cash flow.